WEBULL
WebtradeDownload

Should First Quarterly Profit Require Action From Madrigal Pharmaceuticals (MDGL) Investors?

Simply Wall St · 1d ago
  • Madrigal Pharmaceuticals reported its first profitable quarter in Q3 2026, with net income of US$55.44 million and earnings of US$1.83 per diluted share, driven by blockbuster-level Rezdiffra sales.
  • The shift from large prior losses to profitability, while management continues to fund a broad MASH trial program and commercial build-out, puts Madrigal’s spending discipline and revenue durability under the spotlight.
  • This development raises questions about how Madrigal Pharmaceuticals' first profitable quarter may influence its investment narrative around Rezdiffra-driven earnings.

Scan beyond Madrigal Pharmaceuticals and see how other potential Rezdiffra lookalikes are being valued by reviewing our hand picked 35 high quality undervalued stocks with strong fundamentals and compressed P/S ratios.

Madrigal Pharmaceuticals Investment Narrative Recap

Madrigal Pharmaceuticals now asks shareholders to believe that blockbuster level Rezdiffra demand can support a full commercial build out while funding a heavy MASH trial slate. The first profitable quarter and positive cash generation help that story, but the near term debate still revolves around how much of current prescription volume proves repeatable.

The key short term catalyst is further clinical readouts in more advanced MASH, particularly compensated cirrhosis, which could broaden use and reinforce Rezdiffra’s profile. The biggest current risk remains concentration in a single therapy, so any safety signal, weaker outcomes data or tougher reimbursement environment would quickly feed back into earnings volatility.

The third quarter 2026 earnings release is the most relevant data point. Madrigal Pharmaceuticals moved from a quarterly loss to net income of US$55.44 million, with diluted earnings of US$1.83 per share and year to date Rezdiffra revenue above US$1.1 billion on an annualized run rate above US$1.7 billion, while still posting a nine month loss.

That mix of early profitability and ongoing investment gives management more flexibility as it advances multiple Phase 3 and planned Phase 2 MASH programs and expands commercial reach. It also raises the bar. With the stock trading on a price to sales (P/S) multiple below biotech averages, execution on trial timelines, payer contracts and prescriber growth remains the practical catalyst to watch.

Madrigal Pharmaceuticals' current analyst narrative points to forecast revenue of US$3.2b and projected earnings of US$935.6 million by 2029. That profile is built on an assumed 42.0% yearly revenue growth rate and an earnings swing of about US$1.25b from earnings today of a US$309.4 million loss.

Discover how Madrigal Pharmaceuticals' fair value indicates a 69% potential upside to its current price, which could close faster than many investors expect.

NasdaqGS:MDGL 1-Year Stock Price Chart
NasdaqGS:MDGL 1-Year Stock Price Chart

Exploring Other Perspectives

One alternate view puts reimbursement friction at the center of the Madrigal Pharmaceuticals story instead of blockbuster earnings. The most cautious analysts were penciling in 31.5% annual revenue growth and earnings of about US$282.7 million by 2029 before this profit surprise, a far smaller step up than the consensus. This shows how widely expectations can diverge. Use this earnings break to compare both sets of assumptions and decide which version of the future feels more realistic to you.

Explore 6 other Madrigal Pharmaceuticals fair value estimates, including one that suggests it could be worth just $533.00!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider developing your own view.

Looking For More Investment Ideas Beyond Madrigal Pharmaceuticals?

If the Madrigal Pharmaceuticals story has sharpened your thinking, you can use that same lens across a wider watchlist. The Simply Wall St Screener lets you quickly filter for different traits, whether you care most about value, income, balance sheet strength or a mix of all three.

  • For investors looking for value with quality to support it, review our hand picked 35 high quality undervalued stocks that combine compressed valuations with solid business fundamentals.
  • If income matters to your plan, focus on reliable cash payouts by reviewing a curated set of 5 dividend fortresses that offer higher yields with an emphasis on resilience.
  • When capital preservation is a higher priority than aggressive upside, narrow the universe to a 31 resilient stocks with low risk scores that score well on financial strength and overall risk metrics.